Andisheh Chemotherapy Inc. is a Research and Development company founded in 2015 by a number of academics in organic, medicinal and pharmaceutical chemistry. Andisheh was granted Science-Based Company status by the Office of the Vice President for Science and Technology in 2016. This was based on its record of excellence in Research and Development as demonstrated in numerous scientific publications (115) and international patents (89 and 32 US patents, (see Distinctions). Areas of R&D include process development for de novo production of Category I-V APIs and oral solid drugs including High Potency (HiPo) products such as anticancer products and non-infringing process development based on client’s intellectual property requirements. In 2021, Andisheh was approved by the Ministry of Health for total synthesis, characterization (UV, IR, 1H NMR, 13 C NMR, Mass Spec), purity and assay determination (HPLC) and specification (comparison with primary reference standard procured from established pharmacopeias) of secondary reference standards (SRS or Working Standards, Download catalog). We also offer large-scale separations of enantiomers based on our proprietary process (published and patented by Andisheh). In the area of drug products, Andisheh develops novel non-infringing methods to avoid wet granulation, simplify direct compression without resorting to roller compaction and provides novel formulations of existing drugs to improve bioavailability or to reduce GI side-effects (see Distinctions for example doi. 10.1517/13543776.2011.569493 and WO 2017/199073 Al; US Patent  US 2019/0240144 Al; Iranian Patent 1390/07/27-71996; Iranian Patent 1393/11/13-84942). R&D in biopharmaceuticals includes synthesis and purification of antibody-drug conjugates, API-nanoparticle conjugates and isolation of mAbs by our published and patented proprietary methods (see Distinctions). Our engineering department has successfully designed various closed system manufacturing equipment for the production of category III-V HiPo APIs and oral drug products. The equipment were fabricated domestically for our clients and validated using standard tests such as pressure differential, ammonia, CO2, dispersed oil particulate (DOP) and surrogate using naproxen sodium tests (ISO 14644-1:2015, EU GMP Annex 1, 21 CFR Part 11). Occupational exposure limits (OELs) in various steps of production have been measured and certified by regulatory authorities and found to be considerably below the allowed limits. Accordingly, in addition to Category I and II, our clients were approved by Ministry of Health as Category III-V manufacturer of Hazardous APIs and oral drug products. Andisheh enjoys strong ties with major academic institutions in Iran and a number of our senior scientific staff serve as faculty members and Ph.D. committee members.